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ABSTRACT Several properties of the colchicine-tubulin
interaction such as association rate, reversibility, and the
promotion of drug fluorescence have been related to the B ring
of colchicine. The B ring itself retards the binding rate, and
substitution at C-7 leads to further binding rate decreases that
appear to be related to both substituent bulk and the presence
of a N-acyl group. Thus, the decreasing order of binding rates
is 2-methoxy-5-(2',3',4'-trimethoxyphenyl)tropone > deaceta-
midocolchicine > deacetylcolchicine a colcemid > colchi-
cine > N-benzoyldeacetylcolchicine, etc. The apparent irre-
versibility of the binding seems more closely related to the
presence of an N-acyl group rather than the bulk of the
substituent at C-7. Substitution at C-7 also affects the tropolone
fluorophore. Thus, amines (deacetylcholchicine, colcemid, or
N-methylcolcemid) fluoresce poorly in the presence of tubulin,
whereas substitution of the amino group with an acyl group
enhances fluorescence. The presence of an N-acyl group at C-7
is essential for enhanced fluorescence. We conclude that, in
addition to A- and the C-ring portion ofthe molecule, the B ring
of colchicine is a third determinant recognized by the binding
site on tubulin.
Structure-function relationships in colchicine (Fig. 1) and its
congeners can be conveniently described in terms of the three
rings of the molecule, the A ring or trimethoxybenzene
moiety, the seven-membered B ring, and the methoxytro-
pone moiety or C ring. Substantial evidence has accumulated
that the colchicine-binding site of tubulin, through which
most of the desired drug effect presumably must operate,
contains a domain that recognizes the A ring and a second
domain that recognizes the C ring (1-3). This was first
concluded from the finding that podophyllotoxin competed
for colchicine, presumably through the mutual trimethoxy-
benzene moiety (4). Tropolone and methoxytropone block
colchicine, but not podophyllotoxin, binding (5). It was thus
proposed that colchicine has at least two attachment points
to its binding site on tubulin, one for the A ring and one for
the C ring (4, 5). Subsequently, it was shown (6) that these
domains can be independently occupied by single ring ana-
logues such as mescaline (A ring) or methoxytropone (C
ring). However, affinities for these single rings are low and
marked enhancement of binding affinity is attained when
these are linked as in colchicine, etc. The sum of the
individual binding energies (plus a correction for the cratic
entropy resulting from incorporation of these rings into a
single molecule) was similar to that of colchicine.
Because of the finding that an analogue containing the A
and C rings but lacking the B ring [2-methoxy-5-(2',3',4'-
trimethoxyphenyl)tropone], referred to hereafter as the A-C
compound, has high biological and tubulin binding activity
(7), this compound has been widely used as a simple and
flexible model for colchicine. (Colchicine congeners used in
this study are shown in Table 1; for identification, hereafter,
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FIG. 1. Structure of colchicine analogues used in this study. For
colchicine, R = -NHCOCH3.
these compounds will be followed by their number in Table
1.) It binds rapidly, possibly due to the facile rotation about
the biaryl bond and with an activation energy lower than
colchicine (8) (9, 10). Like colchicine (8), the A-C compound
(16) exhibits marked enhancement of fluorescence upon
binding, and free energies of binding are consistent with the
A- and C-ring contributions (9-11). The contributions of the
B ring to the binding of colchicine congeners to tubulin have
been considered to be of a minor nature. Thus, using the A-C
compound (16) as a model, a bifunctional ligand model has
been proposed for colchicine (8) in which the bulk of the
interactions with the tubulin site, including the conforma-
tional changes in tubulin, are accomplished by the A and C
rings (10, 11). Colchicine (8) binding to tubulin is a two-step
process (12, 13), and it has been proposed that the tropolone
moiety binds before the remainder of the molecule and
promotes the conformational change in the protein that now
facilitates binding of the A ring.
When present, however, B-ring substituents at position
C-7 have major effects on the association and dissociation
rates of the drugs and on the temperature dependence of
binding as exemplified by the difference between colchicine
(8), colcemid (4), and deacetamidocolchicine (1) (8, 9, 14).
Moreover, the unnatural enantiomer, (+)colchicine, shows
no tubulin binding activity (unpublished results). The present
study was undertaken to elucidate the contributions of the B
ring and substitutions at C-7 to the kinetics, binding con-
stants, and fluorescence properties of colchicine analogues.
MATERIALS AND METHODS
Tubulin was prepared by phosphocellulose purification of rat
brain microtubule protein, prepared by two cycles of tem-
perature-dependent polymerization (15) and stored at -70'C
following drop freezing in liquid nitrogen. Fluorescence
measurements were carried out in thermostated cuvettes at
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370C in a Perkin-Elmer MPF 3L instrument with an excita-
tion wavelength of 353 nm and emission at 430 nm except
when stated. GTP was deleted to prevent polymerization.
Corrected emission spectra were measured with a modified
Bowman Aminco spectrofluorometer made available through
the kindness ofRaymond F. Chen. Spectra in 99.5% (vol/vol)
glycerol/0.5% dimethyl sulfoxide were obtained in 5-mm
cells in a Perkin-Elmer MPF 66 instrument at 270C and were
corrected for instrument variation and for solvent contribu-
tions by difference. The quantum yields of colchicine
analogue-tubulin complexes were calculated by comparison
with quinine sulfate in 0.1 M H2SO4, whose quantum yield
was taken as 0.546 at 250C (16).
The binding of colchicine analogues to tubulin was deter-
mined by competition for 1 AM [3H]colchicine (8) binding.
Aliquots (250 1.d) of rat brain tubulin (0.25-0.5 mg/ml) in 100
mM Mes buffer (pH 7.0), 1 mM MgCl2, 1 mM EGTA,[3H]colchicine (8), and analogues (added at the beginning of
the incubation to concentration ranges from 1 to 100 ,M)
were incubated for 60 min at 37°C. The extent of binding was
measured by the DE 81 filter disc method (17). Apparent Ki
values, the amount of colchicine analogue required to inhibit
the [3H]colchicine (8) binding to tubulin by 50%, were then
determined from the semi-log plot of colchicine (8) binding
activity against the concentration of analogue. Colchicine
congeners with different substituents at C-7 were prepared as
described (18-20); the quaternary amine was generously
provided by M. Rosner; it was prepared from colcemid by
reaction with methyl iodide (mp 213-215°C, M++1 = 385).
Deacetamidocolchicine (1) and the A-C compound (16) were
gifts of T. J. Fitzgerald (Florida A & M University).
Association Rate Constant. The bimolecular association
rate constant can be represented as follows:
k= d(CT)/dt[C][T]
where d(CT)/dt is the rate of formation of the complex CT
(colchicine analogue-tubulin) and [C] and [T] are the con-
centrations of free colchicine analogue and unbound tubulin,
respectively. Conditions were adjusted such that <10o ofthe
reactants were consumed during the reaction and progress
curves were linear. We have thus assumed that [C] = [C]Oand[T] = [T]. where [C]O and [T]. are the initial concentrations
of colchicine analogue and tubulin, respectively. The amount
of analogue-bound protein was determined by fluorescence
as follows: [CT] = (Fc/F0) x CO where [CT] = the amount of
complex, F, is the fluorescence of a given solution of
analogue-tubulin complex, and F. is the fluorescence of an
equal concentration of analogue in excess tubulin, such that
all the analogue is bound. Fluorescence of the analogues in
water was negligible at the concentrations used. Each value
of the rate constant is an average of three determinations. In
general, analogue concentration was held constant (3-5 ,uM)
and linear curves were produced over a concentration range
of 3-8 ,M of tubulin.
RESULTS
Equilibrium Constants. Binding constants for colchicine
congeners with different substitutions at C-7 of the B-ring
analogues obtained by displacement of 1 ,uM [3H]colchicine
(8) are listed in Table 1. It is apparent that substitution on the
nitrogen attached to C-7 has an effect on the binding con-
stants obtained but that, despite large variations in the bulk
of the substituents, all constants are within less than an order
of magnitude of colchicine (8). It is of interest that an even
bulkier group (fluorescein isothiocyanate) has been reported
to bind with about 0.10 the affinity of colchicine (8) (21), and
an azidoaromatic photoaffinity label at C-7 with a long spacer(22) and a spin label at C-7 of allocolchicine (23) have good
specificity for the site. It appears, therefore, that this portion
of the B ring has relatively modest effects on this binding
parameter although the introduction of a positive charge
through formation of a quaternary nitrogen causes loss of
binding activity. Another conclusion permitted by the pres-
ent results is that hydrogen bonding between the amino group
and the tropolone carbonyl group is not essential (24) since
the disubstituted analogues N-methylcolchicine (9), N-
methylcolcemid (5), and N-trifluoroacetylcolcemid (11) show
good binding activity. Comparison of these results with the
one point assays performed (2, 20) shows some discrepancies
in the order of affinities, particularly with deacetylcolchicine
(3), N-trifluoroacetylcolcemid (11), N-methylcolchicine (9),
and colcemid (4). Part of these differences can be ascribed to
the fact that highly active analogues were compared on the
nonlinear portion of the dose response curve. It should be
noted that the total absence of the B ring, as, in the A-C
compound (16) listed in Table 1, yields an equilibrium binding
constant of the same order as a number of the analogues
containing the intact B ring (Table 1), as also reported by
others (10, 11).
Binding Rates. Association rate constants were measured
by enhancement of analogue fluorescence that occurs upon
binding to tubulin (25). At the concentrations used, there was
only negligible fluorescence of these compounds in buffer
alone. Quantum yields differ markedly (see below), and all
rates are expressed as a function of the maximal attainable
fluorescence for that particular analogue in the presence ofan
8- to 10-fold excess oftubulin, where all ofthe compound may
be assumed to be bound (see below).
Although colchicine (8) binding has long been known to
exhibit very slow kinetics, there is a very wide range of
binding rates for the colchicine analogues. This is demon-
strated for B-ring analogues at C-7 in Table 1. Association
rate constants vary by nearly four orders of magnitude as we
move from no B ring at all, as exemplified by the A-C
compound (16), to the N-retinoyl (15) derivative at the seven
position. The bare, unsubstituted B ring of deacetamidocol-
chicine (1) causes a 20-fold reduction in the association rate
constant. Substitution at C-7 in the B ring further lowers the
association rate constant, and this occurs as a rough function
of the size of the substituent. It seems possible to propose,
therefore, that the seven-membered B ring itself retards
binding and that substitution at C-7 leads to further rate losses
that appear to be functions both of the bulk and the presence
of a N-acyl group.
Fluorescence. The very slow dissociation of the tubu-
lin-colchicine complex has proved a boon in binding studies
and has been explained (10) by an activation energy barrier
for dissociation that is substantially larger than for the
reversible analogue, A-C compound (16). The binding of
colchicine to tubulin is accompanied by a marked enhance-
ment of fluorescence from the methoxytropone moiety with
characteristics of a 7r*-*ir transition (25, 26) and a lifetime, r,
of 1.14 nsec (13). A substantial fraction of this fluorescence
is caused by the immobilization of this drug in the binding site
on tubulin, rather than being due solely to the hydrophobic
environment that the site may provide (27) since emission can
be elicited from colchicine (8) contained in a sheet of solid
polyvinyl alcohol (26). It has also been suggested that
stabilization of the drug in a conformation that makes the A
and C rings more nearly coplanar contributes to fluorescence
(10).
B-ring substitution at C-7 has a profound effect on the
fluorescence properties of the methoxytropone fluorophore
of colchicine derivatives. This was first suggested (14) by the
poor fluorescence of colcemid. The quantum yields of ana-
logues of colchicine are listed in Table 1 for assays carried out
with an 8- to-10-fold molar excess of tubulin after incubation
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Table 1. Properties of B-ring analogues of colchicine
Fluorescent properties
Fluorescence in
Binding parameters Quantum glycerol
k Iyield of
R group on C-7 of Ki, M-l hr Reversibility,* tubulin Rel. X,,a nm
No. the B ring Name AM (x106) % complex intensityt EX EM
1 H 7-Deacetamidocolchicine 5 6.0 z30 0.023 89 364 465
2 H, (5,6-CH=CH-) 5,6-Dehydro-7-deacetamidocolchicine 5.8 -40 0.013 -
3 NH2 N-deacetylcolchicine 12 1.8 =40 0.0057 66 365 465
4 NHCH3 Colcemid (demecolcine) 60 1.8t 67t =0 64 365 465
5 N(CH3)2 N-methylcolcemid 30 0 57 367 465
6 N+(CH3)3I- N-dimethylcolcemid iodide Inactive - 0 158 364 465
7 N-(CH3)CH2C6H4OH Speciosin 0 32 364 465
8 NHCOCH3 Colchicine 9.4 0.34 =0 0.030 100 365 465
9 N(CH3)COCH3 N-methylcolchicine 30 0.25 Z0 0.032 70 366 465
10 NHCOCF3 N-deacetyl(trifluoracetyl)colchicine 10 0.30 =0 0.026 67 366 465
11 N(CH3)COCF3 N-(trifluoracetyl)colcemid 12 0.18 0 0.028 73 365 465
12 NHCOC6H5 N-deacetyl-N-benzoylcolchicine 24 0.09 =0 0.036 59 364 465
13 NHCOC6H2(OCH3)3 N-deacetyl-N-trimethoxybenzoyl
colchicine 54 0.07 =0 0.029 59 363 465
14 NHCOC(CH3)3 N-deacetyl-N-pivaloylcolchicine 70 0.05 -0 0.0175 105 364 460
15 NH (retinoyl)¶ N-deacetyl-N-retinoylcolchicine 50 0.01 =0 0.018 -
16 A-C compound A-C compound (2, 3)§ 120 >90 0.021 293 365 464
Rel., relative; EX, excitation; EM, emission.
*One hundred times excess of podophyllotoxin for 60 min at 37°C.
tIntensity relative to that of colchicine.
tTaken from ref. 8.
WValues obtained by fluorescence measurements.
CH3'3
¶-CH C(CH3)-CH=CH = C(CH3)- CH= CH-
at 30°C for 60-90 min (to attain plateau values), followed by
separation of the complex and checking for unbound drug.
The unsubstituted B ring or deacetamidocolchicine (1)
gives a fluorescence yield about two-thirds that of colchicine
(8). When a double bond is introduced as in 5,6-dehydro,7-
deacetamidocolchicine (2), the red shift expected from addi-
tion of a double bond conjugated to an aromatic center (28)
occurs in the absorption spectrum (Xma, 358 nm; kma
emission, 431 nm), but there is a reduction in the quantum
yield to = 0.013. Dreyding models suggest that this may be
due to the fact that neither atropisomer can attain the near
coplanar biaryl angle that is possible with the saturated B
ring. This is consistent with the postulate of Bane et al. (10).
Addition of the free amino or alkyl amine groups at position
seven yields analogues that fluoresce very poorly or not at all
when bound to tubulin. By contrast, the N-acyl-containing
derivative exhibits quantum yields on the order of colchicine
(8), and fluorescence is not particularly sensitive to the bulk
of the substituent once the complex is formed. Dreyding
models show that, in one conformation of colchicine (8), the
N-acyl group could approach the ir electrons over the A ring.
To test whether this could enhance fluorescence by supplying
extra electrons to the A ring and thus to the tropolone ring by
extended conjugation, we tested N-deacetylsuccinylcolchi-
cine (prepared from (-)-deacetylcolchicine and succinic
anhydride-mp 255°C, M' + 1 = 468). However, this com-
pound had slightly lower fluorescence than colchicine under
identical conditions (data not shown).
Attempts were made to determine whether the differences
in quantum yield between N-alkyl and N-acyl derivatives of
colchicine were intrinsic properties of the fluorophore or
were the result of the binding interaction with tubulin. To this
end we employed glycerol, which is known to promote
colchicine fluorescence (provided a threshold viscosity of =3
cP is exceeded), albeit less efficiently than tubulin (27). There
is little correlation between the ability of the C-7 substituted
analogues to fluoresce in viscous solvents and the quantum
yields of the tubulin complex (Table 1). It is apparent that
substantially less variation occurs in the relative fluorescence
of the analogues in glycerol than in the tubulin complex.
Note, however, the low fluorescence intensity of speciosin
(7) and the high intensity of the A-C compound (16). Exci-
tation and emission maxima also show only small deviations
from colchicine under these conditions (Table 1). This sug-
gests that the intrinsic fluorescence of the colchicine ana-
logues (as measured in glycerol) is not the primary factor
determining the quantum yields resulting from binding to the
tubulin site. The enhancement by acyl groups is also less
apparent in glycerol. For example, the relative fluorescence
intensity ofdeacetylcolchicine (3) in glycerol contrasts sharp-
ly with the low quantum yield of its tubulin complex, despite
the fact that this compound binds well (Table 1). Similarly,
the absence of fluorescence of the quaternary N-derivative
(6) in the presence of tubulin can be ascribed to the absence
of binding to the site, because it fluoresces well in glycerol.
Such differences between glycerol and tubulin strongly
suggest that B-ring interactions within the binding site con-
tribute to fluorescence and this contribution does not derive
strictly from the affinity of the congener for tubulin.
Proc. Natl. Acad. Sci. USA 83 (1986)
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DISCUSSION
One of the peculiar properties of colchicine binding to tubulin
is the slow equilibration, which often takes 60-90 min.
Garland (12) first proposed a two-step model in which rapid,
reversible binding to tubulin is followed by slow conforma-
tional changes that convert the initial complex to a more
stable, less easily reversible state. This model, with some
modifications, is the currently most used one, and it has been
shown (29) that the promotion of fluorescence best coincides
with the formation of the second complex. The conforma-
tional changes leading to the more stable state have been
postulated to be due to changes in the tubulin molecule, the
colchicine molecule (30, 31), or both. The assumption made
is that initial binding occurs with the skewed conformation
whereas binding to the second state occurs with the more
planar conformer (10).
Is it possible that the B ring or substitutions at C-7
contribute to these conformational changes? Certainly the B
ring provides constraints on the spatial relationship of the A
and C rings to each other. It contributes three properties to
the drug: (i) bulk (both the three carbon chain of the ring and
substituents at C-7), (ii) the N-acyl group, and (iii)
atropisomerism. The present studies clearly show that bulk at
C-7 impedes the binding process, and this effect is greater on
the association rate than on the "equilibrium" constant
(Table 1). On the other hand, the apparent irreversibility of
the binding seems more closely related to the presence of a
N-acyl group, although the nature of its interaction with the
binding site is not clear at present. Since the presence of a
N-acyl group is also associated with higher quantum yields of
the colchicine congener-tubulin complex (Table 1), the ques-
tion of the relation of the irreversibility to the quantum yield
may well be raised. The lower quantum yield (0.021) for the
A-C compound (16), despite its high fluorescence in glycerol
(Table 1), is consistent with a connection between the two
phenomena.
The role of the B ring itself has been more difficult to
rationalize. The drug loses its negative circular dichroic band
at 340 nm, and it was postulated that binding stabilizes
rotation about the biaryl bond from an angle of 53° to 19°,
thereby facilitating extended conjugation and, hence, fluo-
rescence (10, 30). Such a mechanism would explain the
20-fold greater association constant of the A-C compound
(16) compared to deacetamidocolchicine (1) (Table 1), pro-
vided it is assumed that the more planar conformation forms
the stable complex. Additional impediments to approaching
coplanarity appear to occur in 5,6-dehydro,7-deacetamido-
colchicine (2), and the quantum yield is reduced (Table 1). To
what extent these considerations pertain to the excited state
remains to be determined. Whether this effect, or the reduc-
tion of vibrational energy dissipation from the excited state,
is the chief factor promoting fluorescence is difficult to
determine, since both occur as a consequence of binding to
tubulin. In any case, it seems likely that the B ring of
colchicine with the acetamido group at C-7 is a third deter-
minant recognized by the binding site. The domain plays a
major role in the kinetics of binding, reversibility, and the
induction of fluorescence.
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